Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
74 studies found for:    "Multiple Sclerosis, Chronic Progressive"
Show Display Options
Rank Status Study
21 Active, not recruiting Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis
Conditions: Multiple Sclerosis, Primary Progressive;   Multiple Sclerosis, Secondary Progressive
Interventions: Drug: ibudilast;   Drug: Placebo
22 Recruiting ACTH in Progressive Forms of MS
Conditions: Secondary Progressive Multiple Sclerosis;   Primary Progressive Multiple Sclerosis;   Progressive Relapsing Multiple Sclerosis
Interventions: Drug: ACTH;   Drug: Placebo
23 Enrolling by invitation Idebenone for Primary Progressive Multiple Sclerosis
Conditions: Multiple Sclerosis;   Primary Progressive Multiple Sclerosis
Intervention: Drug: Idebenone
24 Active, not recruiting Serial Collection of Primary Progressive Multiple Sclerosis Participants in the MURDOCK Study
Condition: Primary Progressive Multiple Sclerosis
Intervention: Other: generation of 'omic markers of disease progression
25 Completed A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis
Conditions: Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis;   Clinically Isolated Syndrome
Intervention:
26 Completed Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS)
Condition: Multiple Sclerosis
Interventions: Other: Progressive exercise;   Device: Neuromuscular electrical stimulation delivered using the electrical therapy device EMPI 300 PV;   Other: Modified paleolithic diet;   Dietary Supplement: Omega 3 fatty acids;   Dietary Supplement: Full Spectrum vitamin;   Dietary Supplement: Essential - hydroxytyrosol;   Dietary Supplement: Maltodextrin fiber supplement;   Dietary Supplement: Mineral boost (magnesium);   Dietary Supplement: Niacinamide;   Dietary Supplement: Methyl B12;   Dietary Supplement: Taurine;   Dietary Supplement: creatine;   Dietary Supplement: thiamine;   Dietary Supplement: riboflavin;   Dietary Supplement: N acetylcysteine;   Dietary Supplement: alpha lipoic acid;   Dietary Supplement: L acetyl carnitine;   Dietary Supplement: methyl folate;   Dietary Supplement: coenzyme Q;   Behavioral: meditation;   Behavioral: self massage;   Behavioral: learning;   Dietary Supplement: Coconut oil
27 Completed Supported Treadmill Training for Progressive Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Other: Body-weight supported treadmill training
28 Terminated
Has Results
Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)
Condition: Multiple Sclerosis
Interventions: Drug: Rituximab;   Other: normal saline
29 Active, not recruiting A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Condition: Multiple Sclerosis, Primary Progressive
Interventions: Drug: Placebo;   Drug: methylprednisolone;   Drug: ocrelizumab
30 Terminated Hydroxyurea in Primary Progressive Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Hydroxyurea;   Other: placebo
31 Completed Natalizumab Treatment of Progressive Multiple Sclerosis
Conditions: Primary Progressive Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis
Intervention: Drug: Natalizumab
32 Active, not recruiting Double Blind Placebo-Controlled Phase I/II Clinical Trial of Idebenone in Patients With Primary Progressive Multiple Sclerosis (IPPoMS)
Condition: Primary Progressive Multiple Sclerosis
Intervention: Drug: Idebenone
33 Completed FTY720 in Patients With Primary Progressive Multiple Sclerosis
Condition: Primary Progressive Multiple Sclerosis
Interventions: Drug: FTY720;   Drug: Placebo
34 Completed Effect of Interferon Beta-1a (Avonex®) on Changes of Non-Conventional MRI Measures in Patients With MS
Condition: Multiple Sclerosis
Intervention: Drug: Avonex® monotherapy (6.0 MIU administered i.m. each week)
35 Completed Immunological Mechanisms of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Procedure: Stem Cell Transplanataion
36 Withdrawn Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)
Condition: Multiple Sclerosis
Intervention: Drug: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)
37 Completed
Has Results
A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: placebo;   Drug: rituximab
38 Recruiting A Phase 1b, Open-label Study of Liothyronine in MS
Conditions: Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis, Secondary Progressive;   Multiple Sclerosis, Primary Progressive
Intervention: Drug: liothyronine
39 Active, not recruiting Autologous Mesenchymal Stromal Cells for Multiple Sclerosis
Conditions: Relapsing-Remitting Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis
Interventions: Drug: XCEL-MC-ALPHA;   Drug: Placebo
40 Terminated BG00012 and Disability Progression in Secondary Progressive Multiple Sclerosis (SPMS)
Condition: Multiple Sclerosis, Secondary Progressive
Interventions: Drug: dimethyl fumarate;   Other: Placebo

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.